Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
i agree that a lot of this short interest, current day by day trading does mean absolutely NOTHING, but it all soon to be changed. first ADT approval then up-listing.
is that why short interest like around 1 or 2%?? so low that i forgot when was the last time i checked, lol
quote
"As discussed above, the science of abuse deterrence is relatively new. Both the technologies
involved and the analytical, clinical, and statistical methods for evaluating those technologies are
Contains Nonbinding Recommendations
26
rapidly evolving. For these reasons, FDA will take a flexible, adaptive approach to the
evaluation and labeling of potentially abuse-deterrent opioid products. Additionally, there is
considerable room for additional scientific work that could advance the development and
assessment of abuse-deterrent products. In particular, FDA encourages additional research on
the following topics"
pay attention to such words as "FDA is flexible" "the science of abuse deterrence is relatively new" .... any breakout in new tech or science = $$$$$$$$$$$$$$$$$$$$$$$$$$
quote"
FDA is currently considering formal studies plus a variety of supportive information (e.g., data
concerning the street value of prescription drugs) as sources that may be acceptable to provide
evidence that a product’s formulation has had an actual impact on reducing its abuse"
link below to FDA site, interesting read.
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm334743.pdf
it doesn't have to trade on NASDAQ to get proper #s reported, AAPL, BAC and several other blue chip stock i personally trade are not with NASDAQ but being reported.
is that a 2€ euro dollar symbol??)) im ok with that PPS
"""I am sure we will hear the same misinformation at 2¢."""
with that i fully agree
EXACTLY!!! and SHORT sales no one knows UNTIL NASDAQ releases it
you are wasting the $30 then, i hope not per month..i was watching very close to how level2 acts and if my bid is shown when today i placed my 56,500 shares bid @.215 then raised to .218, anyway it got filled @.218 but all levels including LVL2 registered it as a sale. im telling you, me and my friends investors tried to get access to short sales info BUT even with millions of $$ you cant get that!!!!!twise a month Nasdaq officially releases that and thats it. no where else to get it.
revenue is there to support the fundamentals & market cap..i actually think we got absolutely no PPS increase over speculation yet...main reason because of revenue from generics.
Market Cap north of $125,000,000 otherwise.
Thanks to $AAPL profits just added 56,500 shares this AM..46,500 just filled at .218
Just a thought ..why NASDAQ2020 maybe time to switch for NASDAQ2016?)))
Agree, and we dont know the exact details of agreement between patients and recruiting offices and even Camargo...i can't recall to which question Dianne responded , quote "we had patients for march 22nd but without final FDA protocol couldn't proceed"... Honestly for me whether recruited already or not makes no difference. But things like current CEO of Camargo is an ex director of FDA, yea that makes a difference! Those connections, experience always help even if few investors not happy with Camargo timeline.
Answer this: find me another like 2013-2014 year in ELTP history as far as clinical trials, generic lunches, Q over Q revenue growth, decreasing bond debt & etc...? 2015 we will discuss at the end of dec.
You cant, someone might need the surgery before FDA comes back with the protocol
Exact Dianne words quote " we are very excited with recent progress and the ph3 efficacy trial will be over before you even know it.." first thing came to my mind is how excited we were about those 2 label studys being listed on the clinical gov website and all of a sudden only few weeks later studys are complete and we moving forward. Same will be with ph3, today it's recruiting patients-by nect CC we will have results.
Was the 162 patients been updated to 165 already on that gov site? i dont the have chance to check because im on the road and even typing these messages with my phone so excuse my spell check, etc
Thats because you look at it as a "Delay" , i look at it as very important and necessary step that marginally improved our chances to become major pharma. Last thing i think about it is weekly-monthly timeline!
Yep, tired of these flippers games...soon this is all to be over, especially once we are at nasdaq
or as Dianne said ELTP instead of rushing and filling just for the FDA come back and ask for something else, its better to go trough and above the checklist to get FDA approval from the first filing. Its a joke to complain about waiting extra few monts even Qs to get a NEW abuse-deterrent product on the market, im not even talking about a whole pipeline
Oh yeah, basically she mention the "epic investments" being dissolved and im pretty sure thats why you see not to far out (2016) expiration warrants being gifted to friends or family or converted into ELTP shares and from now it's pretty much left Elite Pharma and Epic Pharma...also if you remember Nasrat dissolved Mikah pharma, again reason for less confusion, fillings, etc.
i just talked with Dianne Will from ELTP wish i recorded my conversation because when i asked about recent gifted warrants activity, she gave very detailed explanation. Basically, when in 2009 ELTP and epic investments (dont confuse it with epic pharma) formed partership, certain board members got certain amount of warrants with different expiration dates, so thats what you see in particular last SEC filing that Ashok gifted some of his portion to his family members as a warrants(right to convert into shares). So there is no any kind dilution going on with ELTP behind our backs.
My next question was if she can confirm the Ph3 study we see on gov site is indeed for eli-200 and not eli-201 and if anything else extraordinary happened why FDA delayed commentary on final protocol for ph3 study. She did confirm the only ph3 study going on is for eli-200, now FDA delaying with final protocol is because of last minute patients adjustment from 150 to 165 !
10k indeed to be filled @end of the June,
Thats about it i think
..if I remember anything else , ill post again
Its gonna take 8 weeks to study on all 150 patients from start to finish, im sure they are not going to test all 150 at the same time from day 1.
ALSO i can name few bio companys that were bought out between phase || & phase ||| ... Something to think about it as efficacy trial start sometimes march and to go for 3 months
What time of the day usually ELTP posts ER ??
You are wrong my friend, its "analysts wanna be" post SA article, meaning less for sophisticated investors..i trade BAC , AAPL, RIG and many other blue chip stocks and these SA articles poping out on regular bases, dont pay attention.. imo last run up was due zohydro or whatever news plus pre-er run... Buy/add if can and hold this potential retirement stock!
just opened IRA acc for my self and i realized that recent Nasrat purchase of ELTP in open market had to be with most, if not all his available funds in his IRA account. I base my opinion on the fact that you are only allowed to add $5,000 per year to your IRA, ofcourse we have to consider he had some capital gains from other stocks but its still pushing, so i do believe ELTP is his largest holding in IRA portfolio.
put your money where your mouth is.
Date Order # Type Order Summary Price
Executed Status Related Links
Order
Type Quantity
(Exec / Entered) Symbol Price
Type Term Price
02/04/15 3042 Stock
Buy 43,000 ELTP Limit Day 0.265 Executed 0.2545
02/04/15 10:18:04 AM EST
02/04/15 3036 Stock
Buy 10,000 ELTP Limit Day 0.28 Executed 0.279
02/04/15 09:38:43 AM EST
02/02/15 3023 Stock
Buy 12,000 ELTP Limit Day 0.275 Executed 0.2749
02/02/15 10:02:28 AM EST
its re balance or transfer from one broker account to another unfortunately nothing to get excited about..still .20
holding enough shares, and no i'm not trying to pump the stock by "receiving supposedly email from stuff"
no problem, you maybe now him better then i do, but while holding shares amount of 6 digits i have the right to pay attention to smallest details, and if something doesn't look right, doesn't smell right and particularly shape..then ill call it for what it is, a BS.
lmao))..ill drink to that !!!
Thanks for pullback, added another 30,000 shares
should an effective abuse-deterrent drug be developed, the FDA said it has the power to remove on-the-market rival products which don't.
good read, old article but this will highlight ELTP goal "Over time, it should be a scientific race across the whole pharmaceutical industry to create a market where all opioids have abuse-deterrent properties," said Gary L. Stiles, senior vice president of research and development at the closely held Purdue Pharma.
The race could give a boost to an already lucrative market and raise the cost of pain treatment. A recent Cowen & Co. report predicts an increase in prescription pain drug sales of more than 15% by 2017, reaching $8.4 billion, thanks in part to the FDA ruling. It could also bring about a reshuffling of market share in the fast-growing $7.3 billion pain market, as companies such as Pfizer move with full force in the opioid painkiller market for the first time.
The FDA isn't directly requiring all painkillers to have safeguards. But should an effective abuse-deterrent drug be developed, the FDA said it has the power to remove on-the-market rival products which don't.
Drug companies are racing to conduct the studies and research required by the FDA to prove their drugs thwart abuse. Winning that distinction from the FDA, as Purdue Pharma has done for OxyContin, allows company sales representatives to tout those properties to doctors—forming a potential new marketing battleground for branded drugs. "That's how you're going to see the battle going forward," said Mike Royal
no, it can be next month or next year..but if you be prepared to wait a year any earlier date is gravy on top.
its FDA, they play by their own rules and their time frame..as long as i get something in about a year im ok with that. meanwhile commercial generics pipeline is growing(revenues)
yes im on with same access code, no problem at all
Never mind, its optionshouse platform screwed up, on etrade bid .039 and ask .56